Are GLP-1 Medications Really Covered by Medicare? What Patients Need to Know in 2026

You may have recently heard that Medicare now covers GLP-1 medications for weight loss. That statement is partly true—but it does not mean every Medicare patient can receive any GLP-1 medication simply because their provider recommends it.

Beginning July 1, 2026, Medicare introduced a temporary program called the Medicare GLP-1 Bridge. The program offers certain eligible patients access to selected medications for a $50 monthly copayment. However, eligibility is limited, prior authorization is required, and only specific medications and formulations are included. The temporary program is currently scheduled to end on December 31, 2027.

The real question is not simply, “Does Medicare cover GLP-1s?”

It is: Will Medicare cover the medication you need, for your specific diagnosis, without delays or interruptions?

Who May Qualify for Medicare’s GLP-1 Bridge?

Having Medicare does not automatically make someone eligible. A patient must have Medicare Part D prescription coverage and meet specific medical criteria.

Under the current requirements, a patient must generally meet one of the following:

• A body mass index, or BMI, of 35 or higher.

• A BMI of at least 30 with certain qualifying conditions, such as heart failure with preserved ejection fraction, uncontrolled high blood pressure despite treatment, or stage 3a or higher chronic kidney disease.

• A BMI of at least 27 with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.

  
  

The BMI requirement is based on the patient’s weight when GLP-1 therapy was originally started. The prescribing provider must document and certify that the patient meets the applicable criteria.

Patients with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or certain forms of fatty liver disease are not eligible for the Bridge based on those diagnoses. Instead, they may need to request coverage through their regular Medicare Part D plan under the medication’s approved indication. That means the individual insurance plan’s formulary and authorization rules may apply.

Medicare Does Not Cover Every GLP-1 Medication

The Medicare GLP-1 Bridge currently includes only:

• Foundayo® tablets

• Wegovy® injections or tablets

• Zepbound® KwikPen®

  
  

The program does not cover every dosage form. For example, Zepbound single-dose vials and single-dose pens are not included. Pen needles for the Zepbound KwikPen are also not covered through the Bridge.

Ozempic® and Mounjaro® may be covered through a Medicare Part D plan when prescribed for an eligible type 2 diabetes indication, but they are not automatically covered simply for weight management.

What Red Tape Is Involved?

Even when a patient appears to qualify, coverage is not automatic.

The prescriber may need to complete a prior authorization confirming:

• The patient’s BMI when treatment was initiated.

• The qualifying medical condition.

• The reason the medication is being prescribed.

• That the patient is participating in ongoing nutrition and lifestyle modification.

• That the requested medication and formulation are covered by the program.

• Whether the patient has a diagnosis that should instead be processed through the regular Part D plan.

  
  

Once approved under the Bridge, the authorization is generally valid through December 31, 2027. However, a new authorization is required if the patient changes from one covered GLP-1 medication to another.

Patients seeking coverage through a standard Medicare Part D plan may face additional insurance requirements. Medicare drug plans are permitted to use:

• Prior authorization

• Step therapy, which may require trying another medication first

• Quantity limits

• Formulary restrictions

• Medical-necessity reviews

  
  

When a drug is not covered or an insurance requirement cannot be met, the patient or prescriber may need to request a formulary exception or appeal. The prescriber must usually submit medical documentation explaining why covered alternatives would not be effective or could cause adverse effects.

Can Coverage Change After Treatment Begins?

Yes.

The Medicare GLP-1 Bridge is a temporary demonstration rather than a permanent expansion of the standard Medicare Part D benefit. It currently runs only through December 31, 2027. What happens after that date will depend on future federal decisions.

Regular Medicare drug plans may also change their formularies when new medications become available, treatment guidelines change, or new medical information is released. A medication that was preferred during one coverage year may require a different authorization, move to another cost-sharing tier, or be replaced by a preferred alternative in a future year.

For patients, these changes can lead to:

• Delays while new paperwork is submitted.

• Requests to switch medications.

• Unexpected increases in out-of-pocket costs.

• Appeals and exception requests.

• Interruptions in treatment when approval cannot be obtained promptly.

  
  

This does not mean Medicare coverage is not worth pursuing. For a patient who qualifies for the $50 Bridge program, it may be the most affordable option. However, patients should understand that insurance coverage and reliable access are not always the same thing.

Where Compounded GLP-1 Care May Offer Value

Some patients will not satisfy Medicare’s BMI or diagnosis requirements. Others may be prescribed a medication or formulation that their plan does not cover. Patients can also become frustrated by repeated calls, authorizations, denials, pharmacy issues, or insurance-directed medication changes.

When medically appropriate and legally available, self-pay compounded GLP-1 care may provide another option.

Because treatment is not submitted to an insurance drug plan, patients are not dependent on:

• A Medicare formulary.

• An insurance company’s preferred medication.

• Step-therapy requirements.

• Diagnosis-specific coverage rules.

• Insurance authorization before treatment can begin.

• Annual changes to a prescription plan’s drug list.

  
  

At WNY Wellness, the value is not limited to receiving medication. Patients receive care from a local medical team that can evaluate their health history, develop an individualized treatment plan, monitor progress, address side effects and adjust treatment when clinically appropriate.

Our medical weight-loss program includes:

• An in-person initial evaluation.

• Ongoing provider oversight.

• Clear, self-pay pricing.

• Medication and injection education.

• Local support when questions or side effects arise.

• Access to our team outside regular office hours.

• Care at our Lockport and Williamsville locations.

• Same-day treatment initiation when medically appropriate.

  
  

Rather than depending on a mail-order program or an insurance call center, patients have a local team that knows their treatment history and can help them navigate the process.

Important Information About Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness or quality before they are marketed in the same way it reviews FDA-approved products. Compounded treatment should only be prescribed when a qualified medical provider determines it is appropriate for an individual patient and should be obtained from a properly licensed pharmacy.

Patients should avoid websites or sellers that offer GLP-1 medications without a legitimate medical evaluation. The FDA has warned about fraudulent products, inaccurate labels, dosing errors and illegal online sales. Proper prescribing, clear dosing instructions and ongoing medical monitoring are essential.

Which Option Is Right for You?

For patients who qualify, Medicare’s new $50 GLP-1 Bridge may provide significant savings and is worth exploring.

However, the program does not cover every patient, medication, diagnosis or formulation. It also does not eliminate prior authorization or guarantee permanent coverage.

For patients who are not eligible—or who want a predictable, locally managed treatment option—WNY Wellness may be able to offer an alternative through our self-pay medical weight-loss program.

Medical weight loss should be managed around the patient—not around a shipping schedule, an insurance formulary or a call-center script.

WNY Wellness provides real medical oversight, local support and clear pricing at our Lockport and Williamsville clinics.

Schedule a free initial consultation to learn which treatment options may be appropriate for you.

Individual eligibility, medication selection and treatment decisions are based on a medical evaluation. Coverage rules and government programs may change. WNY Wellness does not guarantee Medicare or insurance approval. Compounded medications are not FDA-approved.